SATB1 gene expression and breast cancer prognosis
SATB1 gene expression and breast cancer prognosis
复制标题
DOI：
10.1016/j.breast.2010.10.002
复制
发表时间：
2011-08-01
期刊：
影响因子：
3.9
通讯作者：
Wiegratz, Inka
中科院分区：
文献类型：
--
作者：
Hanker, Lars C.;Karn, Thomas;Wiegratz, Inka
最近研究表明，基因组组织者SATB 1在乳腺癌进展中起重要作用，并预测预后不良。然而，与雌激素受体标记物相比，其预后价值目前尚不清楚。分析了2058例乳腺癌样本队列中来自Affyphin微阵列的SATB 1 mRNA表达水平及其预后影响。ER阴性癌症的无病生存率没有显著差异，但ER阳性肿瘤中SATB 1高表达的益处（p = 0.042）。然而，即使在ER阳性的癌症中，也没有观察到标准参数的多变量分析的独立预后价值。因此，使用SATB 1作为乳腺癌的靶点或预后标志物应谨慎对待，在分析新的标志物SATB 1时，应考虑肿瘤雌激素受体状态的可能混淆效应。(C)2010爱思唯尔有限公司版权所有。
Recently it has been shown that the genome organizer SATB1 plays an important role in breast cancer progression and predicts a poor prognosis. However its prognostic value compared to markers as the estrogen receptor is currently unclear. The expression levels of SATB1 mRNA from Affymetrix microarray in a cohort of 2058 breast cancer samples and its prognostic impact were analyzed. There was no significant difference in disease-free survival among ER negative cancers but instead a benefit for high SATB1 expression among ER positive tumors (p = 0.042). However, even in ER positive cancer no independent prognostic value in multivariate analysis with standard parameters was observed. Thus the use of SATB1 as target or prognostic marker for breast cancer should be viewed with caution and a possible confounding effect of the estrogen receptor status of the tumor should be taken into account when analysing new markers as SATB1. (C) 2010 Elsevier Ltd. All rights reserved.